Breast cancer is among the most actively researched cancers in the US, with hundreds of clinical trials enrolling at any given time across all stages, subtypes, and treatment phases. Trials cover the full spectrum from prevention and early-stage adjuvant therapy through metastatic disease, with rapid evolution in HER2-targeted, hormone-positive, and triple-negative breast cancer treatments. For patients, clinical trials for breast cancer offer access to advanced therapies that may not be available outside research settings, particularly for metastatic or treatment-resistant disease. This guide covers how to find breast cancer trials, the major categories being tested, eligibility considerations, and resources for enrollment.
Categories of breast cancer trials
Active breast cancer trials in 2026 cover:
HER2-positive breast cancer: Antibody-drug conjugates (ADCs) including next-generation versions of trastuzumab deruxtecan (Enhertu), bispecific antibodies, and combinations of HER2-targeted therapies with other agents.
Hormone receptor-positive breast cancer: Next-generation selective estrogen receptor degraders (SERDs), CDK4/6 inhibitor combinations, PI3K-pathway inhibitors, and novel endocrine therapies for treatment-resistant disease.
Triple-negative breast cancer: Immunotherapy combinations, PARP inhibitors in expanded indications, antibody-drug conjugates including sacituzumab govitecan extensions, and targeted therapies for specific molecular subtypes.
Early-stage adjuvant therapy: Trials testing whether intensified or de-escalated treatment regimens improve outcomes in early breast cancer.
Prevention trials: Studies in high-risk women without cancer testing whether interventions can prevent breast cancer development.
Survivorship and supportive care: Trials addressing fatigue, cognitive effects, lymphedema, and quality of life issues in breast cancer survivors.
Where to find breast cancer trials
Resources for finding breast cancer trials:
- ClinicalTrials.gov — comprehensive federal database
- National Cancer Institute clinical trial search — curated NCI-supported trials with patient-friendly summaries
- BreastCancerTrials.org — specific to breast cancer with detailed matching
- Susan G. Komen — research and trial resources
- Breastcancer.org — patient education and trial information
- NCI-Designated Cancer Centers — major academic centers running extensive trial programs
For metastatic breast cancer specifically, trials at NCI-Designated Comprehensive Cancer Centers often include the most innovative therapies. The 71 NCI-Designated Cancer Centers are listed on the NCI website.
Subtype-specific trial considerations
Breast cancer is a heterogeneous disease, and trial eligibility usually depends on subtype:
Hormone receptor status (ER/PR): Estrogen receptor and progesterone receptor positivity determined by IHC staining
HER2 status: HER2-positive (3+ by IHC or amplified by FISH), HER2-low (1-2+ IHC, FISH negative), HER2-zero
BRCA mutation status: Germline BRCA1/BRCA2 mutations are eligibility criteria for some trials (PARP inhibitor studies particularly)
PIK3CA mutation status: Mutations in PIK3CA matter for some targeted therapy trials
Stage: Early-stage (Stages 0-III) vs metastatic (Stage IV) trials have very different designs
Patients should know their tumor’s complete molecular profile, including standard immunohistochemistry results and any genomic testing results. This information is essential for matching with appropriate trials.
Typical eligibility for breast cancer trials
Common inclusion criteria:
- Confirmed breast cancer diagnosis with specific subtype requirements
- Stage and treatment history matching the trial’s target population
- Adequate organ function (liver, kidney, bone marrow, cardiac)
- Performance status (ECOG 0-2 typically — ability to perform daily activities)
- Specific lab values within ranges
- Adequate time from prior therapies (washout periods)
Common exclusion criteria:
- Other active malignancies
- Brain metastases (some trials exclude; others specifically target brain mets)
- Recent chemotherapy or radiation (within specific windows)
- Pregnancy (almost universally excluded)
- Significant cardiac disease (especially for trials of cardiotoxic drugs)
- Specific prior therapy history that disqualifies (e.g., prior CDK4/6 inhibitor)
What participation involves
Breast cancer trials typically involve:
- Comprehensive baseline workup including imaging, labs, ECG, sometimes biopsies
- Randomization in randomized trials, often to experimental treatment vs current standard of care
- Regular treatment cycles based on the drug being tested (often every 3-4 weeks)
- Frequent imaging (typically every 6-12 weeks) to assess tumor response
- Lab monitoring for toxicity
- Quality of life and symptom assessments
- Long-term follow-up after treatment ends
Total time commitment varies enormously. Trials in metastatic breast cancer can continue indefinitely for patients who respond to treatment. Adjuvant therapy trials often have defined treatment durations of 6-12 months followed by years of follow-up.
Trials in metastatic disease
Patients with metastatic breast cancer often have the strongest case for trial participation. Standard treatments may have failed or have significant toxicity, and trials may offer access to advanced therapies like:
- Antibody-drug conjugates targeting HER2, TROP2, and other markers
- Bispecific antibodies engaging multiple immune mechanisms
- Novel hormone receptor targeting agents
- Combinations of immunotherapy with other therapies
- Targeted therapies for specific molecular subtypes
For metastatic disease, comprehensive genomic testing of the tumor (or circulating tumor DNA) is often necessary to identify trial-eligible mutations. Many academic centers offer this testing as part of routine care.
Adjuvant and neoadjuvant trials
Trials in early-stage breast cancer test whether adding, intensifying, or de-escalating treatment improves outcomes. Examples include:
- Adjuvant CDK4/6 inhibitors (like the abemaciclib monarchE trial that established adjuvant use)
- Adjuvant olaparib for BRCA-mutated breast cancer
- De-escalation trials testing whether less treatment is equivalent
- Neoadjuvant immunotherapy trials in triple-negative disease
These trials often involve large sample sizes (1,000+ patients) and long follow-up to assess outcomes like disease-free survival.
Prevention trials
Women at high risk of breast cancer (family history, BRCA mutations, prior atypical hyperplasia) can participate in prevention trials testing whether interventions reduce cancer development. Examples include:
- Anti-estrogen therapies in high-risk women (tamoxifen, raloxifene, aromatase inhibitors)
- Vaccine trials targeting molecular changes in pre-cancerous breast tissue
- Lifestyle intervention trials (exercise, diet, weight loss)
The Breast Cancer Research Foundation and the National Cancer Institute support extensive prevention research.
Frequently Asked Questions
Are breast cancer trials only for patients without other treatment options?
No. Trials enroll across all stages and treatment lines. Some trials are specifically for patients receiving first-line treatment; others target patients whose disease has progressed on standard therapies. Trials for early-stage disease often run alongside standard treatment.
Will I get the standard of care if I’m in a trial?
Most modern breast cancer trials use active comparators rather than placebo — meaning you’ll receive either the experimental treatment or the current standard of care. Pure placebo controls are rare except in specific scenarios.
How important is the cancer subtype for trial matching?
Critical. Most trials are subtype-specific. HER2-positive, hormone-positive, and triple-negative trials are largely separate. Knowing your complete tumor molecular profile is essential.
Can I participate in a trial at one hospital while getting standard care elsewhere?
Some trials allow this; others require care at the trial site for safety monitoring. The protocol specifies. Coordinate carefully to avoid duplicate treatments or gaps.
What if I have brain metastases?
Some trials exclude patients with brain metastases; others specifically target this population. Brain mets are a major issue in HER2-positive breast cancer particularly. Specific trials for CNS metastases exist.
The bottom line on breast cancer trials
Breast cancer is among the most actively researched cancers with hundreds of active trials covering all subtypes and stages. For patients with metastatic or treatment-resistant disease, trials offer access to advanced therapies before approval. Subtype-specific matching matters — know your tumor’s molecular profile. NCI-Designated Cancer Centers and major academic medical centers offer the most extensive trial programs. Discuss trial options with your oncologist as part of comprehensive treatment planning. For patients with strong performance status and adequate organ function, trial participation often expands rather than replaces standard care options.